230 related articles for article (PubMed ID: 27225938)
1. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.
Tao LY; Zhang LF; Xiu DR; Yuan CH; Ma ZL; Jiang B
World J Surg Oncol; 2016 May; 14():146. PubMed ID: 27183870
[TBL] [Abstract][Full Text] [Related]
3. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
4. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
5. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
6. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
[TBL] [Abstract][Full Text] [Related]
9. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
10. Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers.
Mottini C; Cardone L
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708716
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
13. Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens.
Sho S; Court CM; Kim S; Braxton DR; Hou S; Muthusamy VR; Watson RR; Sedarat A; Tseng HR; Tomlinson JS
PLoS One; 2017; 12(1):e0170897. PubMed ID: 28125707
[TBL] [Abstract][Full Text] [Related]
14. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A; Krausz S; Strijker M; van der Wel MJ; Soer EC; Reinten RJ; Besselink MG; Wilmink JW; van de Vijver MJ; van Noesel CJM; Verheij J; Meijer SL; Dijk F; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):394-403. PubMed ID: 28801248
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.
Ogura T; Yamao K; Hara K; Mizuno N; Hijioka S; Imaoka H; Sawaki A; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Bhatia V; Higuchi K; Hosoda W; Yatabe Y
J Gastroenterol; 2013 May; 48(5):640-6. PubMed ID: 22983505
[TBL] [Abstract][Full Text] [Related]
19. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
20. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
